STAGE III BLADDER CANCER AJCC V8

This study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…

This early-phase trial tests the safety and best dose of a combination of two or three drugs (cabozantinib, nivolumab, and possibly ipilimumab) in people with advanced genitourinary cancers that have spread. About 152 adults with these cancers will participate. The goal is to fin…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can improve outcomes for people with stage III bladder cancer that has spread to nearby lymph nodes. About 95 adults will receive either chemoradiation alone or chemoradiation…

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder cancer that has spread or come back. The trial includes 72 adults whose cancer cannot be treated with the standar…

This study tests a combination of two drugs, tazemetostat and pembrolizumab, in 30 people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. Participants must have had prior chemotherapy that…

This study aimed to test two treatments for muscle-invasive bladder cancer in patients who cannot receive the standard chemotherapy drug cisplatin. The treatments were erdafitinib (a targeted pill) alone or combined with atezolizumab (an immunotherapy). The goal was to see if the…

This study tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from progressing after initial chemotherapy. About 654 adults with advanced bladder, kidney, or ureter cancer that has spread will receive either the combo or avelu…

This study tests a drug called olaparib in people with advanced bladder or other genitourinary cancers that have specific DNA-repair defects. Olaparib works by blocking a protein that cancer cells need to repair their damaged DNA, which may stop the cancer from growing. The trial…

This study looks at whether certain genetic changes in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Researchers are testing tumor samples for specific gene mutations and a protein called CXCL13. The…